医学
肝硬化
非酒精性脂肪肝
非酒精性脂肪性肝炎
胰岛素抵抗
内科学
中医药
炎症
疾病
纤维化
脂肪性肝炎
脂肪肝
生物信息学
胰岛素
病理
生物
替代医学
作者
Mingtai Chen,Ying Xie,Shenglan Gong,Yunqiao Wang,Hao Yu,Tianran Zhou,Furong Huang,Xin Guo,Huanhuan Zhang,Ruolan Huang,Zhiyi Han,Yufeng Xing,Qiang Liu,Guangdong Tong,Hua Zhou
标识
DOI:10.1016/j.phrs.2021.105849
摘要
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease in clinical practice. It has been considered that NASH is one of the main causes of chronic liver disease, cirrhosis and carcinoma. The mechanism of the NASH progression is complex, including lipid metabolism dysfunction, insulin resistance, oxidative stress, inflammation, apoptosis, fibrosis and gut microbiota dysbiosis. Except for lifestyle modification and bariatric surgery, there has been no pharmacological therapy that is being officially approved in NASH treatment. Traditional Chinese medicine (TCM), as a conventional and effective therapeutic strategy, has been proved to be beneficial in treating NASH in numbers of studies. In the light of this, TCM may provide a potential therapy for treating NASH. In this review, we summarized the associated mechanisms of action TCM treating NASH in preclinical studies and systematically analysis the effectiveness of TCM treating NASH in current clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI